List of Excipients in Branded Drug SYMPAZAN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Aquestive Therapeutics	SYMPAZAN	clobazam	10094-205	CITRIC ACID MONOHYDRATE
Aquestive Therapeutics	SYMPAZAN	clobazam	10094-205	GLYCERYL MONOOLEATE
Aquestive Therapeutics	SYMPAZAN	clobazam	10094-205	HYPROMELLOSES
Aquestive Therapeutics	SYMPAZAN	clobazam	10094-205	MALTITOL

Sympazan Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

Sympazan is an FDA-approved clobazam oral film for Lennox-Gastaut syndrome. Its commercial differentiation comes from the dosage form rather than a new active ingredient: a rapidly dissolving, water-free film that can simplify administration for pediatric and neurologically impaired patients. The excipient system supports film formation, handling, mouthfeel, taste acceptance, and dose uniformity. Its strongest commercial opportunities are lifecycle expansion, pediatric adherence, international licensing, and platform-based development of other controlled substances and rescue medicines.

What is Sympazan and how does its oral film work?

Sympazan contains clobazam, a 1,5-benzodiazepine, in 5 mg, 10 mg, 20 mg, and 40 mg oral film strengths. The product is approved as an adjunctive treatment for seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. The FDA approved Sympazan under NDA 209888 in November 2018. [1]

The film is placed on top of the tongue, where it dissolves without water. This delivery method addresses several administration problems associated with conventional tablets and suspensions:

• Difficulty swallowing in children and patients with neurological impairment.
• Dependence on water or measuring devices.
• Dosing interruptions during travel, school, hospitalization, or seizure-related emergencies.
• Potential manipulation or spillage associated with liquid formulations.
• Caregiver burden when patients resist tablets or have impaired swallowing.

Sympazan is not an abuse-deterrent product and does not eliminate the pharmacologic risks associated with clobazam, including sedation, dependence, withdrawal, and respiratory depression when combined with other central nervous system depressants. Its value proposition is administration convenience and patient usability.

What excipients are used in Sympazan?

The Sympazan labeling identifies a conventional oral-film excipient architecture consisting of a water-soluble film former, plasticizer, bulking or structural agents, sweetener, and flavoring components. The inactive ingredients listed in the FDA prescribing information include maltodextrin, glycerin, hypromellose, mannitol, sucralose, and natural and artificial flavoring. [1]

Excipient or excipient class	Primary formulation function	Commercial relevance
Hypromellose	Film formation, tensile strength, dissolution control	Determines strip integrity and handling
Maltodextrin	Film matrix and solids carrier	Supports manufacturability and mouthfeel
Glycerin	Plasticizer	Reduces brittleness and improves flexibility
Mannitol	Bulking agent, mouthfeel modifier, sweetness contribution	Supports palatability and low-residue dissolution
Sucralose	High-intensity sweetener	Masks clobazam bitterness
Natural and artificial flavors	Taste and odor masking	Supports pediatric acceptability

The public label does not disclose quantitative excipient concentrations. That information is commercially important because the balance between hypromellose, maltodextrin, glycerin, and mannitol affects film strength, residual moisture, dissolution time, packaging requirements, and manufacturing yield.

Why hypromellose is strategically important

Hypromellose is likely the central structural polymer in the film. Its grade, viscosity, substitution pattern, particle characteristics, and concentration can affect:

• Wet-film viscosity.
• Drying behavior.
• Strip tensile strength.
• Flexibility during slitting and packaging.
• Dissolution rate on the tongue.
• Drug dispersion and content uniformity.

A higher polymer load may improve mechanical strength but slow disintegration and increase mouth residue. A lower load may improve dissolution but create brittle films, edge defects, or dose-uniformity problems. For a low-dose benzodiazepine, the formulation must distribute clobazam uniformly across a thin film despite the relatively small drug load.

Why glycerin and mannitol matter

Glycerin functions as a plasticizer. It reduces brittleness, but excessive glycerin can increase tackiness, moisture uptake, and packaging risk. Glycerin levels also influence how the film behaves after exposure to humidity.

Mannitol contributes solids, sweetness, and cooling mouthfeel. It can improve patient acceptance, but its crystallization behavior must be controlled. Changes in mannitol particle size, grade, or processing conditions can alter film texture and dissolution.

Taste masking requirements for clobazam

Clobazam is a bitter, centrally acting drug. Taste masking is therefore a core commercial requirement, not a cosmetic feature. The Sympazan excipient system uses sucralose and flavoring rather than relying solely on a physical barrier coating.

The formulation challenge is to suppress bitterness during the short residence time in the mouth while allowing rapid drug release. Excessive taste-masking polymer or coating could delay release and complicate dose uniformity. A successful formulation must balance:

1. Immediate wetting.
2. Rapid film breakup.
3. Low bitter perception.
4. Minimal residue.
5. Acceptable flavor persistence.

This creates opportunities for excipient suppliers with high-purity film-forming polymers, co-processed sweetener systems, flavor encapsulation, and moisture-control technologies.

What FDA regulatory status and exclusivity apply to Sympazan?

Sympazan is an NDA product, not a biologic. Biosimilar competition is therefore irrelevant. The principal future competitive pathway is an abbreviated new drug application, or ANDA, for a pharmaceutically equivalent clobazam oral film.

Regulatory item	Sympazan status
Active ingredient	Clobazam
Dosage form	Oral film
Indication	Lennox-Gastaut syndrome
NDA	209888
FDA approval	November 2018
Regulatory pathway	505(b)(2) or NDA development for the innovator product
Likely follow-on pathway	ANDA, subject to FDA product-specific requirements
NCE exclusivity	Not applicable because clobazam was previously approved
New-dosage-form exclusivity	Three-year exclusivity associated with approval of the new dosage form, subject to FDA listing and timing rules
Biosimilar exposure	Not applicable

The three-year statutory exclusivity associated with a new dosage form would not create a long-term barrier by itself. Long-term protection depends on Orange Book-listed patents, formulation know-how, manufacturing controls, trademarks, and commercial scale.

What patents protect Sympazan?

Sympazan protection is expected to rely on a combination of dosage-form, formulation, manufacturing, and use claims rather than composition-of-matter protection for clobazam. Clobazam was already a known active pharmaceutical ingredient before Sympazan approval.

The relevant protection categories are:

Oral-film formulation patents

These claims may cover a film containing clobazam, a polymer matrix, plasticizer, sweetener, and flavor system. Claim scope can depend on:

• Polymer identity and concentration.
• Drug loading.
• Film thickness.
• Dissolution profile.
• Residual moisture.
• Mechanical strength.
• Specific excipient combinations.

Formulation claims are valuable when they require a combination that is difficult to design around without sacrificing manufacturability or patient acceptance.

Method-of-use patents

Sympazan's core indication is adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. Method-of-use claims may address patient populations, dosing regimens, administration conditions, or treatment outcomes. These claims can complicate generic launch if they are listed in the Orange Book and remain enforceable, but they are generally narrower than composition claims.

Manufacturing and process protection

Process protection may cover preparation of the drug-containing casting solution, drying conditions, film cutting, content-uniformity controls, or packaging. Process claims can create practical barriers even when a competitor avoids the exact formulation.

Trade secrets are particularly important for oral films. The public label does not reveal:

• Casting or coating parameters.
• Drying temperature and residence time.
• In-process moisture limits.
• Film tension and slitting conditions.
• Flavor premix preparation.
• Acceptable defect thresholds.
• Packaging line settings.

These controls can be more difficult to replicate than the ingredient list.

Orange Book status and Paragraph IV risk

The FDA Orange Book determines whether listed patents can trigger a 30-month stay after a Paragraph IV certification and timely patent litigation. A generic applicant could challenge listed patents by asserting that they are invalid, unenforceable, or not infringed.

For Sympazan, the highest-value Paragraph IV targets would likely be:

• Broad clobazam oral-film composition claims.
• Claims covering the specific excipient matrix.
• Claims that require a defined dissolution or stability profile.
• Manufacturing claims that read on standard solvent-casting processes.

A generic applicant could also pursue a Paragraph III certification, waiting for patent expiration, or a section viii statement carving out patented methods of use where permitted. The practical outcome would depend on the current Orange Book listings and the claims of each patent. [2]

When does Sympazan lose exclusivity?

Sympazan's regulatory exclusivity and patent exclusivity should be analyzed separately.

The three-year new-dosage-form exclusivity associated with the 2018 approval would not extend beyond the early 2020s. The commercial launch date for a lawful generic depends on the latest enforceable patent, settlement terms, pediatric exclusivity, regulatory approval, and any litigation stay.

Protection layer	Commercial effect
Three-year new-dosage-form exclusivity	Delayed certain ANDA approvals after the 2018 approval
Orange Book patents	May delay approval or launch if challenged
Pediatric exclusivity	Could add six months to qualifying patents if granted
Formulation trade secrets	May force a design-around
Manufacturing know-how	Can delay reliable commercial scale-up
Trademark and branding	Limits substitution-driven brand recognition but does not prevent generic approval

No NCE exclusivity should be assumed for Sympazan because clobazam was previously approved. The key commercial question is the duration and breadth of the listed patent estate, not NCE protection.

How strong is the Sympazan patent estate?

The patent estate is strategically useful but structurally narrower than the estate for a new chemical entity. Its strength depends on whether claims cover the marketed product specifically or only broad oral-film concepts.

Estate characteristic	Assessment
Active ingredient protection	Weak or unavailable for Sympazan because clobazam is an established drug
Dosage-form protection	Potentially significant
Excipient-combination protection	Potentially significant if claims are narrow and technically supported
Method-of-use protection	Moderate, depending on claim scope and indication
Manufacturing protection	Often difficult for competitors to detect and challenge
Design-around risk	Material because competitors can alter polymers, sweeteners, flavors, or film architecture
Regulatory substitution risk	Lower than for a standard tablet if FDA-rated equivalence is difficult to establish
Trade-secret value	High for process parameters and scale-up controls

The strongest barrier is likely the combination of formulation performance and regulatory complexity. A competitor may reproduce the ingredient list but still face challenges in matching content uniformity, dissolution, stability, taste, and manufacturing yield.

What generic entry risks exist for Sympazan?

Generic entry is technically possible but more complex than a conventional clobazam tablet. A competitor would need to establish pharmaceutical equivalence and bioequivalence while demonstrating a reproducible oral-film product.

Key development risks include:

• Dose uniformity across a thin strip.
• Film thickness variation.
• Moisture-driven degradation or loss of mechanical strength.
• Differences in dissolution and drug release.
• Taste and mouthfeel failure.
• Packaging protection against humidity.
• Difficulty matching the reference product's dosage-form specifications.
• Patent claims directed to excipient combinations or manufacturing steps.

The most credible generic launch scenario is a design-around film using a different polymer-plasticizer system, provided the applicant can satisfy FDA requirements. A tablet or liquid generic may not be therapeutically substitutable for the oral film unless it is approved in the same dosage form and receives the relevant FDA therapeutic-equivalence designation.

What commercial opportunities exist for Sympazan excipients?

Pediatric and caregiver-focused line extensions

The most direct opportunity is improving pediatric acceptability. Potential development areas include:

• Lower-residue films.
• Shorter dissolution time.
• More neutral flavor profiles.
• Unit-dose packaging for school and travel.
• Dose-flexible films or scored formats, where legally and technically appropriate.
• Packaging with improved moisture protection.

These changes could support lifecycle management, but new strengths or formulations would require regulatory review.

International commercialization

Oral films can have particular value in markets where access to water, dosing devices, or refrigeration is inconsistent. International opportunities include licensing to regional epilepsy specialists, local packaging partnerships, and country-specific flavor systems.

A major constraint is regulatory classification. Some jurisdictions may treat the product as a conventional oral dosage form, while others may require extensive bridging data for the film technology. Patent term, pediatric exclusivity, and local data requirements also vary by country.

Excipient supplier opportunities

Suppliers can compete for Sympazan-like products through differentiated excipient platforms:

• Direct-compression or film-grade hypromellose.
• Low-moisture maltodextrin.
• Nonhygroscopic plasticizers.
• Co-processed mannitol systems.
• Encapsulated flavors.
• Taste-masking technologies.
• High-barrier unit-dose packaging.
• Continuous film-casting equipment.

Supplier value is highest when the excipient improves both patient acceptance and manufacturing economics. A lower-cost excipient that increases rejects, drying time, or packaging failures is unlikely to create a durable advantage.

Platform expansion by Aquestive

Aquestive's oral-film platform can support products beyond clobazam, particularly where administration difficulty, rapid use, controlled-substance handling, or caregiver convenience affects demand. The commercial logic is strongest for drugs with:

• A low or moderate dose.
• Poor tablet acceptance.
• A need for rapid administration.
• Pediatric or geriatric use.
• A clear adherence problem.
• Existing intellectual-property or regulatory differentiation.

The platform can create value even when the active ingredient is generic, because dosage-form patents, manufacturing know-how, and regulatory execution may support a differentiated product.

What patent litigation and licensing issues affect Sympazan?

No material Sympazan-specific litigation or settlement terms should be assumed without a current docket and Orange Book review. The relevant disputes would involve patent validity, infringement, Paragraph IV certifications, and the scope of any generic applicant's proposed dosage form.

Public company disclosures should also be examined for licensing obligations, royalty payments, product rights, and milestone arrangements. Sympazan's commercial economics cannot be calculated from the ingredient list alone because net revenue, royalties, manufacturing cost, rebates, and selling expenses determine product profitability. Aquestive's public filings report corporate financial performance, but standalone Sympazan economics may not be fully disaggregated. [3]

How does Sympazan compare with clobazam tablets and oral suspensions?

Attribute	Sympazan oral film	Clobazam tablet	Clobazam oral suspension
Water required	No	Usually yes	No
Dose measurement	Unit film	Tablet strength	Measuring device
Swallowing burden	Low	Higher	Low
Pediatric usability	Potentially favorable	Variable	Favorable
Taste challenge	Immediate oral exposure	Limited before swallowing	High
Manufacturing complexity	High	Moderate	Moderate to high
Generic design-around risk	Moderate	High	Moderate
Packaging sensitivity	Potentially high	Lower	Moderate
Differentiation	Dosage form and convenience	Limited	Liquid administration

Sympazan's premium depends on whether caregivers and prescribers value the film enough to offset the availability of lower-cost tablets and suspensions. The strongest market segment is patients who cannot reliably swallow tablets or whose caregivers need a portable, water-free dosage form.

Key Takeaways

• Sympazan is a clobazam oral film approved for Lennox-Gastaut syndrome under NDA 209888 in 2018.
• Its excipient system uses hypromellose, maltodextrin, glycerin, mannitol, sucralose, and flavoring to balance film strength, flexibility, dissolution, and taste.
• Clobazam's prior approval means Sympazan does not rely on NCE exclusivity.
• Long-term protection depends on oral-film patents, manufacturing know-how, Orange Book listings, and commercial execution.
• Generic entry is technically feasible but requires control of film uniformity, moisture, taste, dissolution, and packaging.
• The highest-value commercial opportunities are pediatric adherence, lifecycle reformulation, international licensing, excipient platforms, and expansion into other difficult-to-administer medicines.
• Biosimilar competition is not relevant because Sympazan is a small-molecule drug.

FAQs

Can Sympazan excipients be copied by a generic manufacturer?

A generic manufacturer can review the public inactive-ingredient list, but the exact concentrations and manufacturing parameters are generally not disclosed. Patents, process controls, stability requirements, and performance specifications may still require a design-around.

Is Sympazan more commercially defensible than a clobazam tablet?

Yes, in dosage-form terms. The oral film creates greater formulation and manufacturing complexity. That advantage does not prevent generic competition, but it may raise development costs and reduce the speed of substitution.

Do Sympazan excipients create patentable subject matter?

They can. Patentability may arise from a specific excipient combination, defined dissolution or mechanical properties, taste-masking performance, moisture limits, or a manufacturing process. A generic list of commonly used excipients is less likely to provide strong protection without technical differentiation.

Could Sympazan be reformulated without sucralose?

A reformulation could use another sweetener or taste-masking system, but it would require evaluation of bitterness, stability, dissolution, patient acceptability, and regulatory comparability. Removing sucralose would not automatically improve the product.

What is the main commercial threat to Sympazan?

The main threat is a lower-priced clobazam product that achieves therapeutic substitution or captures patients who do not require the oral-film format. A second threat is a competing oral film with better taste, faster dissolution, lower cost, or broader international availability.

References

1. U.S. Food and Drug Administration. (2018). Sympazan (clobazam) oral film prescribing information. NDA 209888.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Aquestive Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
5. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.